Mucormycosis in Australia: contemporary epidemiology and outcomes

KJ Kennedy, K Daveson, MA Slavin, SJ van Hal, TC Sorrell, A Lee, DJ Marriott, B Chapman, CL Halliday, K Hajkowicz, E Athan, N Bak, E Cheong, Christopher H. Heath, C O O Morrissey, S Kidd, R Beresford, Christopher C. Blyth, TM Korman, J.O O RobinsonW Meyer, S.C C Chen

    Research output: Contribution to journalArticle

    31 Citations (Scopus)


    Mucormycosis is the second most common cause of invasive mould infection and causes disease in diverse hosts, including those who are immuno-competent. We conducted a multicentre retrospective study of proven and probable cases of mucormycosis diagnosed between 2004–2012 to determine the epidemiology and outcome determinants in Australia. Seventy-four cases were identified (63 proven, 11 probable). The majority (54.1%) were caused by Rhizopus spp. Patients who sustained trauma were more likely to have non-Rhizopus infections relative to patients without trauma (OR 9.0, p 0.001, 95% CI 2.1–42.8). Haematological malignancy (48.6%), chemotherapy (42.9%), corticosteroids (52.7%), diabetes mellitus (27%) and trauma (22.9%) were the most common co-morbidities or risk factors. Rheumatological/autoimmune disorders occurred in nine (12.1%) instances. Eight (10.8%) cases had no underlying co-morbidity and were more likely to have associated trauma (7/8; 87.5% versus 10/66; 15.2%; p <0.001). Disseminated infection was common (39.2%). Apophysomyces spp. and Saksenaea spp. caused infection in immuno-competent hosts, most frequently associated with trauma and affected sites other than lung and sinuses. The 180-day mortality was 56.7%. The strongest predictors of mortality were rheumatological/autoimmune disorder (OR = 24.0, p 0.038 95% CI 1.2–481.4), haematological malignancy (OR = 7.7, p 0.001, 95% CI 2.3–25.2) and admission to intensive care unit (OR = 4.2, p 0.02, 95% CI 1.3–13.8). Most deaths occurred within one month. Thereafter we observed divergence in survival between the haematological and non-haematological populations (p 0.006). The mortality of mucormycosis remains particularly high in the immuno-compromised host. Underlying rheumatological/autoimmune disorders are a previously under-appreciated risk for infection and poor outcome. © 2016 European Society of Clinical Microbiology and Infectious Diseases
    Original languageEnglish
    Pages (from-to)775-781
    Number of pages7
    JournalClinical Microbiology and Infection
    Issue number9
    Publication statusPublished - 2016

    Fingerprint Dive into the research topics of 'Mucormycosis in Australia: contemporary epidemiology and outcomes'. Together they form a unique fingerprint.

  • Cite this

    Kennedy, KJ., Daveson, K., Slavin, MA., van Hal, SJ., Sorrell, TC., Lee, A., Marriott, DJ., Chapman, B., Halliday, CL., Hajkowicz, K., Athan, E., Bak, N., Cheong, E., Heath, C. H., Morrissey, C. O. O., Kidd, S., Beresford, R., Blyth, C. C., Korman, TM., ... Chen, S. C. C. (2016). Mucormycosis in Australia: contemporary epidemiology and outcomes. Clinical Microbiology and Infection, 22(9), 775-781.